Patent number: 6602897
Abstract: A compound of formula I or of formula II
wherein:
R1 is F, Cl, Br, CH2F, CF2H, or CF3;
R2 is NR6R7, where R6 is Me, Et, Pr, or iPr, and R7 is Me, Et or Pr; and
R3, R4, and R5 independently of one another each are H, Me, F, Cl, Br, CH2F, CF2H, or CF3,
and if R4 is Me, F, Cl, Br, CH2F, CF2H, or CF3, then R1 is additionally H or Me,
or a pharmacologically acceptable salt thereof. In addition, pharmaceutical compositions comprising an effective amount of these compounds, methods for the treatment or prophylaxis of urinary incontinence and diseases of the bladder using these compounds, and methods for making these compounds are disclosed.
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
August 5, 2003
Assignee:
Boehringer Ingelheim Pharma KG
Inventors:
Franz Esser, Pascale Pouzet, Hisato Kitagawa, Kenji Sakai, Ikunobu Muramatsu
Patent number: 6514969
Abstract: Compounds of general formula (I)
wherein:
A is —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CO—, —CH2—CH2—CO—, or —CH═CH—CO—;
Het is piperidinyl, piperazinyl, or dihydrobenzimidazolonyl;
R1 is hydrogen or halogen;
R2 is hydrogen, C1-C4-alkyl, CF3, or a phenyl group optionally substituted by halogen, C1-C4-alkyl, or C1-C4-alkyloxy; and
R3 is hydrogen, C1-C4-alkyl, HO—C1-C4-alkyl, or C2-C4-alkenyl; or a group selected from phenyl, benzyl, and phenylethyl, each optionally substituted by halogen, CF3, C1-C4-alkyl, or C1-C4-alkyloxy; or a heterocycle selected from among morpholine, piperidine, piperazine, and dihydrobenzimidazolone, the heterocycle either linked directly or via a C1-C4-alkylene bridge,
or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of
Type:
Grant
Filed:
July 24, 2001
Date of Patent:
February 4, 2003
Assignee:
Boehringer Ingelheim Pharma KG
Inventors:
Hans Briem, Klaus Mendla, Helmut Michael Romig, Katja Fechteler, Klaus Fuchs
Patent number: 6492407
Abstract: A method for treating a neurodegenerative disease or cerebral ischemia arising from conditions selected from the group consisting of Status epilepticus, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotonia, cardiac infarction, brain pressure (elevated intracranial pressure), ischaemic and haemorrhagic stroke, global cerebral ischaemia with heart stoppage, diabetic polyneuropathy, tinnitus, perinatal asphyxia, psychosis, schizophrenia, depression, and Parkinson's disease, the method of treatment comprising administering to a host in need of such treatment a therapeutic amount of a compound of formula (I)
wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing a compound of formula (I).
Type:
Grant
Filed:
April 23, 2001
Date of Patent:
December 10, 2002
Assignee:
Boehringer Imgelheim Pharma KG
Inventors:
Michael Brenner, Wolf-Dietrich Bechtel, Rainer Palluk, Marion Wienrich, Thomas Weiser
Patent number: 6455538
Abstract: Compounds of general formula I
wherein X is a single bond, —O—, C-C4-alkylene, or an alkylene bridge having 1 to 8 carbon atoms which may be branched or unbranched and optionally have one or two oxygen atom(s) anywhere in the bridge; R1 is hydrogen, methyl, ethyl, or phenyl; R2 is hydrogen or methyl; R3 is hydrogen, fluorine, chlorine, bromine, hydroxy, methyl, or methoxy; R4 is hydrogen, methyl, or ethyl; R5 is hydrogen, methyl, or ethyl; R6 is hydrogen, methyl, or ethyl; R7 is tert-butyl, cyclohexyl, phenyl optionally substituted by R9 and R10, which may be identical or different, or;
R8 is hydrogen or C1-C4-alkyl; Z is oxygen, NH, or sulfur; R9 is hydrogen, methyl, fluorine, chlorine, bromine, or methoxy; R10 is hydrogen, methyl, fluorine, chlorine, bromine, or methoxy; optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates as well as in the form of the free bases or the corresponding acid addition salts
Type:
Grant
Filed:
March 10, 2000
Date of Patent:
September 24, 2002
Assignee:
Boehringer Ingelheim Pharma KG
Inventors:
Matthias Grauert, Adrian Carter, Wolf-Dietrich Bechtel, Thomas Weiser, Rainer Palluk, Uwe Pschorn